Nicholas Augustinos, Director, on September 14, 2026, sold 8,089 shares in Dexcom (DXCM) for $679,769. Following the Form 4 filing with the SEC, Augustinos has control over a total of 34,868 common shares of the company, with 5,575 shares held directly and 29,293 controlled indirectly.
SEC Filing:
Michael F Montoya, Chief Technology Operations Officer, on September 14, 2026, sold 4,426 shares in F5 (FFIV) for $1,815,380. Following the Form 4 filing with the SEC, Montoya has control over a total of 1,309 common shares of the company, with 1,309 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1048695/000186946626000012/xslF345X05/wk-form4_1789508922.xml
Paul C Joseph, Executive Vice President, Global Sales, on September 15, 2026, sold 3,100 shares in Akamai Technologies (AKAM) for $327,453. Following the Form 4 filing with the SEC, Joseph has control over a total of 28,666 common shares of the company, with 28,472 shares held directly and 194 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1086222/000184557426000018/xslF345X05/wk-form4_1789507920.xml
Robert A Frist Jr, 10% Owner, Director, CEO and Chairman, on September 14, 2026, sold 144,068 shares in Healthstream (HSTM) for $4,250,006. Following the Form 4 filing with the SEC, Frist has control over a total of 5,005,375 common shares of the company, with 3,907,038 shares held directly and 1,098,337 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1095565/000143774926030481/xslF345X05/rdgdoc.xml